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ARF in the ICU - mid 80’s
CRRT
5%
peritoneal
dialysis 5%
intermittent
hemodialysis 90%
 Intermittent HD is the 
treatment of choice for any 
type of ARF.
 CRRT started to develop.
 Peritoneal dialysis is still 
being practiced.
ARF in the ICU - late 90’s
CRRT
27%
intermittent
hemodialysis
73%
 CRRT
Western Europe  40%
North America   15%
Japan 10% (?)
 Peritoneal Dialysis has 
disappeared.
3rd Millennium
IHD
10 to 20%
CRRT
80 to 90%
 CRRT has become the 
treatment of choice for 
critically ill patients with 
Acute Renal Failure.
 IHD remaining only for 
uncomplicated ARF.
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Pathophysiology and definitions of the five subtypes of cardio-renal syndrome 
(modified by Ronco et al.105)
Ronco C et al. Eur Heart J 2010;31:703-711
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
RIFLE criteria/staging system for RF
Epidemiology of AKD
The prevalence of AKD among patients in
the intensive care unit is not known.
• As many as 70% of critically ill patients 
experience some degree of AKD.
Approximately 5% of patients in the ICU
receive renal replacement therapy (e.g.,
hemofiltration, hemodialysis).
• Hospital mortality in this group is 40-80% 
Mortality
ARF is an independent predictor of a poor renal outcome
Vascular/ cardiac surgery – ARF increases mortality
Cardiac surgery patients
Matched illness severity / comorbidities
• 63% mortality dialysis
• 4.3 % mortality intact renal function
Am J Med 1998; 104 (4) 343-348
Predictors of mortality
Multisystem failure
Mechanical ventilation
Hypoalbuminemia
Hyperbilirubinemia
Severe Lactic acidosis
Dialysis requirement
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In cardio-renal syndromes, there are two important aspects: the first is the 
sequence of organ involvement and the second is the bi-directionality of 
signalling leading to a vicious cycle.
Ronco C et al. Eur Heart J 2010;31:703-711
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
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Risk factors for acute renal insufficiency after cardiac surgery.
Kolh P Eur Heart J 2009;30:1824-1827
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
How do we assess a patient with AKI?
 Is this acute or chronic renal failure?
– History and examination
– Previous serum creatinine measurements
– Small kidneys on ultrasound (except for in -
Diabetes, PCKD, Urinary Tract Obstruction)
Hilton et al, BMJ 2006;333;786-790
Distinguishing between acute and chronic renal 
failure is important, as –
– The approach to these patients differs greatly.
– This may, save a great deal of unnecessary 
investigation.
Factors that suggest chronicity include:
– Long duration of symptoms,
– Nocturia,
– Absence of acute illness, anaemia, 
hyperphosphatemia, and hypocalcaemia,
Has obstruction been excluded?
– Complete anuria
– Palpable bladder
– Renal ultrasound
– X – Ray
– CT scan
Is the patient euvolaemic?
– Pulse, JVP/CVP, postural blood pressure, daily 
weights, fluid balance
– Disproportional increase in urea /creatinine ratio
– Urinary sodium concentration (unless on diuretics)
– Fluid challenge
Management principles in ARF
 Identify and correct pre-renal and post-renal factors
 Optimise cardiac output and RBF-
 Review drugs: 
– Stop ACEI, ARBs, NSAIDs 
– Adjust doses / monitor drug concentrations (where 
appropriate)
Avoid
 Aminoglycosides
– 33 % of nephrotoxicity “therapeutic levels”
 Amphotericin 
– hydration,
– Liposomal formulation
 Radiocontrast media -
– Hydration
– N-acetyl cysteine
Management principles
 Accurately monitor fluid balance and daily body 
weight
 Identify and treat acute complications
– Hyperkalaemia,
– Acidosis,
– Pulmonary oedema
 Identify and aggressively treat infection;
– Minimise indwelling lines
– Remove bladder catheter if anuric.
 Identify and treat bleeding tendency: 
– Prophylaxis - proton pump inhibitor or H2 
antagonist, avoid aspirin
– transfuse if required
Optimise nutritional support
Maintaining calories enhances patient survival
Maintaining protein intake MAY enhance 
recovery & outcome
Protein intakes of > 1.2- 1.4 g/kg/ day can 
dramatically increase urea production 
WITHOUT evidence of outcome benefit
Treatment of AKD
Goals of therapy are to prevent death, reduce complications, 
hasten/permit renal recovery
Effective
 Hemodialysis
 Biocompatible
membranes
 More dialysis
Unknown
 CRRT vs. IHD  
 Earlier dialysis
 Initiate dialysis before uraemic complications set in
Ineffective/harmful
Diuretics *
Dopamine
* Diuretics are never a treatment for oliguria but
are sometimes required for management of
volume overload.
Kellum JA, Leblanc M, Venkatraman, R.
Clinical Evidence. 2004; 11:1094-118.
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Surgical techniques and pharmaceutical agents used to decrease 
the incidence of acute renal insufficiency (ARI) after cardiac 
surgery
Kolh P Eur Heart J 2009;30:1824-1827
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
Open heart surgery procedures
(2000-01.06.2010  N=8217 pts)
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Number of operations per year N=8217 pts
N= 7252 cardiac surery
N= 965 vascular suregry
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Renal replacement therapy on cardiac 
surgery intensive care unit
N=8217 pts.
n=794 (9,6%)pts.- renal 
insufficiency
666 (83.8%) with coronary 
disease
-115 (14.5%) with terminal valve 
disease
-3 (0.5%) congenital heart 
failure
-10 (1,3%) peripheral vascular 
disease
-625 (78,7%) conservative treatment
- 169 (21,3%) RRT
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Trends and treatment possibilities
Prisma Flex  - CRRT (treatment 
of ARF and CRF) 
26.10.2008 first procedure
169 (21,3%) pts with RRT
(mortality rate 14,8%-25pts)
10 (5,9%) with vascular surgery
(mortality rate 0 )
25 (14,8%) with valve surgery
(mortality rate 16%-4pts)
15 (8,9%) postop.sepsis
(mortality rate 40% -6pts)
119 (70,4%) with CABG
(mortality rate 12,6%-15pts)
CRRT (2000-2010)
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Gambro AK 200
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Postoperative monitoring
Prisma Flex  - CRRT (treatment of ARI and 
CRI) 26.10.2008 first procedure
Advantages:
Normal water balance
Electrolyte control
Coagulation control
Decreasing of serum urea 
and creatinine level
Good patient comfort-
without muscle cramps, 
hypoglycemia, paresthesis 
and vomitingOld fashioned techniques - CAVH,
CVVH
Gambro AK 200
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CABG - RRT
119 (70,4%) with CABG
(mortality rate 12,6%-15pts)
10-pts –operated in OPCAB
0 mortality rate
No one with ARF
3- CRF – treated with Prismaflex 
GAMBRO
109pts operated CABG with 
HLM
15pts treated with CRRT –
Prismaflex Gambro CVVHD
12of them with ARF (HLM 
elfluence and preoperative low 
CO Sy)
3 pts with CRF- CVVHD
10 (5,9%) with vascular surgery
(mortality rate 0 )
10 pts CRRT – CVVHD 
GAMBRO Prismaflex
10 pts CRF 
Day before op. HD
Next day continue with CVVHD
CRRT Prismaflex v.s. other types of 
RRT (Gambro AK200, CAVH,CVVH)
142(84,1%)
27(15,9%)
PRSIMAFLEX GAMBRO 
others
CRRT Prismaflex v.s. other types of 
RRT (Gambro AK200, CAVH,CVVH)
2(7,4%)
23(16,2%)
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CRRT – Prismaflex 
Gambro mortality rate 
7,4% (2pts)
Other mortality rate
16,2% (23pts)
Case Report
 B.M. 65y man 
 09.09.2008 –CABG x3&LV aneurysmectomy & mitral 
reconstruction, EF 25% IABP, Sy low cardiac output
 21.09.2008 – discharged EF- 35%
 25.12.2008 re-admission pulmonary oedema,
 Sy low cardiac output, pO2,pCO2 
inversion(pCO298,pO2 45), CVP-28mmHg, MAP-
45mmHg
 ARF-anuria (urea 38,creat.264), cathelolamines doesn’t 
work
 Severe acidosis
Case Report
Intubation, PEEP
 No blood gass improvement
 Cathecholamines – still doesn’t work
 PRISMAFLEX – GAMBRO –SCUF
 Urgent negative balance – blood gas improvement
 Haemodynamic stability
 BGA correction
 Normal parameters on respiratory machine
 Percutaneous tracheotomy
 Home discharge 18.01.2009
Follow up period 1 year 7 months

